When bringing a new health technology to market in England, pharmaceutical and biotech companies mus...
Read moreThe increasing complexity of bringing innovative therapies to market across various jurisdictions pr...
Read moreWith the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...
Read moreAs the regulatory and market access landscape continues to evolve across Europe, timely and strategi...
Read moreIn the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu...
Read moreThe first joint clinical assessments under the new EU Health Technology Assessment (HTA) Regulation ...
Read moreThe long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...
Read moreOn 21 March 2025, the European Commission hosted a public webinar to share updates on the implementa...
Read moreCelebrating its 25th anniversary, NICE hosted a conference looking back at its progress and ahead to...
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...
Read more